Prospects for a vaccine against the hepatitis C virus

被引:240
作者
Houghton, M
Abrignani, S
机构
[1] Chiron Corp, Emeryville, CA 94608 USA
[2] INGM, Natl Inst Mol Genet, I-20122 Milan, Italy
关键词
D O I
10.1038/nature04081
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
The recent discovery of natural immunity to the hepatitis C virus and vaccine efficacy in the chimpanzee challenge model has allowed optimism about the development of at least a partly effective vaccine against this heterogeneous pathogen that is responsible for much of the chronic liver disease around the world. The immune systems of some infected individuals can spontaneously clear the virus, whereas other people need treatment with antivirals that work partly by stimulating humoral and cellular immune responses. Therefore, therapeutic vaccine strategies are also being pursued to improve treatment outcome.
引用
收藏
页码:961 / 966
页数:6
相关论文
共 73 条
[1]
Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct ctokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells [J].
Abel, K ;
Wang, YC ;
Fritts, L ;
Sanchez, E ;
Chung, E ;
Fitzgerald-Bocarsly, P ;
Krieg, AM ;
Miller, CJ .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (05) :606-621
[2]
Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins [J].
Abraham, JD ;
Himoudi, N ;
Kien, F ;
Berland, JL ;
Codran, A ;
Bartosch, B ;
Baumert, T ;
Paranhos-Baccala, G ;
Schuster, C ;
Inchauspé, G ;
Kieny, MP .
VACCINE, 2004, 22 (29-30) :3917-3928
[3]
Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome [J].
Alter, HJ ;
Seeff, LB .
SEMINARS IN LIVER DISEASE, 2000, 20 (01) :17-35
[4]
In vitro assay for neutralizing antibody to hepatitis C virus:: Evidence for broadly conserved neutralization epitopes [J].
Bartosch, B ;
Bukh, J ;
Meunier, JC ;
Granier, C ;
Engle, RE ;
Blackwelder, WC ;
Emerson, SU ;
Cosset, FL ;
Purcell, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14199-14204
[5]
Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection [J].
Bassett, SE ;
Guerra, B ;
Brasky, K ;
Miskovsky, E ;
Houghton, M ;
Klimpel, GR ;
Lanford, RE .
HEPATOLOGY, 2001, 33 (06) :1479-1487
[6]
Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C [J].
Baumert, TF ;
Wellnitz, S ;
Aono, S ;
Satoi, J ;
Herion, D ;
Gerlach, JT ;
Pape, GR ;
Lau, JYN ;
Hoofnagle, JH ;
Blum, HE ;
Liang, TJ .
HEPATOLOGY, 2000, 32 (03) :610-617
[7]
Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles [J].
Brinster, C ;
Chen, M ;
Boucreux, D ;
Paranhos-Baccala, G ;
Liljeström, P ;
Lemmonier, F ;
Inchauspé, G .
JOURNAL OF GENERAL VIROLOGY, 2002, 83 :369-381
[8]
An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent ΔE1-E2-E3-E4 Ad5 vectors [J].
Catalucci, D ;
Sporeno, E ;
Cirillo, A ;
Ciliberto, G ;
Nicosia, A ;
Colloca, S .
JOURNAL OF VIROLOGY, 2005, 79 (10) :6400-6409
[9]
VACCINATION OF CHIMPANZEES AGAINST INFECTION BY THE HEPATITIS-C VIRUS [J].
CHOO, QL ;
KUO, G ;
RALSTON, R ;
WEINER, A ;
CHIEN, D ;
VANNEST, G ;
HAN, J ;
BERGER, K ;
THUDIUM, K ;
KUO, C ;
KANSOPON, J ;
MCFARLAND, J ;
TABRIZI, A ;
CHING, K ;
MOSS, B ;
CUMMINS, LB ;
HOUGHTON, M ;
MUCHMORE, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) :1294-1298
[10]
COATES S, 2005, P 11 INT S VIR HEP L, P118